Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Protalix BioTherapeutics (PLX)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: PLX
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
52wk high:
52wk low:
EPS:
PE:
Dividend:
Yield:
Market Cap:
Exchange:
Analysis - Latest Articles
Genzyme: Focusing on Lumizyme Approval
Mark Mitchell
•
Oct 30
•
Comment!
BioMed News Bytes: Protalix, Soligenix
Mike Havrilla
•
Oct 15
•
Comment!
Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited
Mark Mitchell
•
Oct 06
•
3 Comments
Sell Genzyme Near Term Due to Continued Manufacturing Challenges
Mark Mitchell
•
Sep 24
•
2 Comments
Genzyme: Short Term Traders Are Throwing Out the Baby with the Bathwater
Ken Majmudar
•
Sep 16
•
Comment!
Protalix Wins Orphan Drug Status for Gaucher Disease Treatment
Zacks.com
•
Sep 10
•
Comment!
More articles on PLX »
Instablogs
Moving past earnings; focus is now on Lumizyme approval
Thu October 29, 2009
•
Mark Mitchell
•
Comment!
Trial setback is welcome news for Genzyme, but don't get too excited...
Mon October 5, 2009
•
Mark Mitchell
•
1 Comment
Genzyme update highlights challenges with manufacturing biologics; reiterate near-term SELL
Wed September 23, 2009
•
Mark Mitchell
•
Comment!
Write a post on PLX
|
More Instablogs on PLX »
Sentiment
What advice would you give to
PLX?
124 characters left
What's your view of PLX?
Make sure you include PLX
140 characters left
|
Settings